Drug Interaction:
Corticosteroids topical include-
Alcometasone dipropionate, Amcinonide, Betamethasone benzoate, dipropionate, valerate, Clobetasol propionate, clocortolone pivalate, Desonide, Desoximetasone, Dexamethasone, Diflorasone, Fluocinolone acetonide,Fluocinonide, Flurandrenolide, Fluticasone propionate, Halcinode, Halobetasol Propionate, Hydrocortisone, Methylprednisolone acetate, Mometasone furoate, Prednicarbate, Triamcinolone acetonide
Refer - Betamethasone
Indication:
U.S. FDA APPROVED DRUGS FROM 01-01-08 TO 31-12-08
Drug name Indication Date of Approval
87. Betamethasone 0.05% 12-03-08 + Miconazole 2% Cream
For the treatment of steroid responsive dermatoses
with superficial fungal infections of the skin
FIXED DOSE COMBINATIONS APPROVED BY DCG(I) FROM JANUARY 1961 TILL NOVEMBER 2014
Name of Drug Indication Date of Approval 2%
1.Betamethasone 0.05% + 12-03-2008
Miconazole 2% cream
For the treatment of steroid responsive dermatoses associated with
superficial fungal infections of the skin
2. Betamethasone Disprop 0.064% + 14-05-2002
Salicylic acid 3% each ml lotion
For the treatment of keratosis, ichthylysis, lichen planus & dry
scaly conditions of skin
3. Betamethasone Diprop 0.064% + 25-09-2002
Gentamicin sulphate eq. to Gentamycin 1mg per ml
suspension lotion
Treatment of infectant dermatoses infection eczema, & contact
dermatitis topical
4.Betamethasone Diprop 6.43mg + July- 1984
Betamethasome phosphate 2.63mg each vial
Anti-inflammatory conditions
Corticosteroids topical include-
Alcometasone dipropionate, Amcinonide, Betamethasone benzoate, dipropionate, valerate, Clobetasol propionate, clocortolone pivalate, Desonide, Desoximetasone, Dexamethasone, Diflorasone, Fluocinolone acetonide,Fluocinonide, Flurandrenolide, Fluticasone propionate, Halcinode, Halobetasol Propionate, Hydrocortisone, Methylprednisolone acetate, Mometasone furoate, Prednicarbate, Triamcinolone acetonide
Refer - Betamethasone
Adverse Reaction:
Local -
Burning, itching, irritation, erythema, folliculitis, hypertrichosis, pruritus, acneform eruptions, hyperpigmentation, perioral dermatitis, allergic contact dermititis, numbness of the fingers, stinging and cracking /tightening of skin, maceration of skin, secondary infection, skin atrophy, stariae.
These may occur more frequently with occlusive dressings
Systemic-
Systemic absoprtion of topical corticosteroids have produced reversible HPA axis suppression, manifestations of Cushings syndrome,hypeglycemia and glycosuria. This is more likely to occur with occlusive dressings and with potent steroids.
Patients with liver failure or children with children may at higher risk. Following prolonged application around the eyes , cataracts and glaucoma may occur. In diffused atrophied skin, blood vessels may become visible on the skin surface
Contra-Indications:
Hypersensitivity to any component,
monotherapy in primary bacterial infections such as impetigo, paryonchia, celluititis.
Warnings-
Pregnancy - Corticosteroids are teratogenic in animlas when administered systemically at relatively doses.
Therefore use during pregnancy only if potential benefits outweigh thepotential hazards to the fetus. In pregnant women do not use extensively, do not use in large amounts or for prolonged periods of time
. Lactation- excercise caution when administering topical corticosteroids to a nursing mother
Children- Children may be more susceptible to topical corticosteroid induced hypothalamic -pituitary-adrenal (HPA ) axis suppression and Cushings syndrome than adults because of a larger skin surface area to body ratio
Special precautions:
Systemic effects- Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, Cushings syndrome, hyperglycemia, and glycosuria Conditions that augument systemic absoprtion include
-
- application of more potent steroids
-
- use over large surface areas
-
- prolonged use and addition of occlusive dressings
Local irritation- if local irritation develops discontinue use and institute appropiate therapy Medications containing alcohol may produce skin or buring sensation/irritation in open lesions
Skin atrophy is common and may be clinically significant in 3 to 4 weeks with potent preparations
Take care when using periorbitally or in the genital areas.
Avoid use of high potency topical corticosteroids on the face
Psoriasis- do not use topcal corticosteroids as sole therapy in wide spread plaque psoriasis
Infections- in the presence of infections institute therapy with an antifungal or antibacterial agent
For exernal use only - avoid inhalation of aerosols ingestion, or contact with eyes
Occlusive dressings- discontinue use of occlusive medicines if infection develops and institute appropiate antimicrobial therapy
Dosages/ Overdosage Etc:
Date of approval July 1984
Indications:
Anti-inflammatory conditions
Dosage:
0.5 to 5mg daily.
Other Information:
For Availability/supplies
Contact -
1.Indian Drug Manufacturers Association (IDMA)
Phone- 022- 24944624/ 24974308
Fax- 022- 24950723
Email- idma@vsnl.com
Website: www.idma-assn.org
2.Bulk Drug Manufacturers Association (India)(BDMA)
Phone - 040-23703910/ 23706718
Fax- 040-23704804
Email- info@bdmai.org
Website: www.info@bdmai.org
Patient Information:
1. Apply ointments, creams, or gel sparingly in a light film, rub it gently. Washing or soaking the areas before application may increase drug penetration
2. To use a lotion, solution or gel on your scalp, part your hair , apply a small amount of the medicine on the affected area and rub it gently. protect the area from washing, clothing, rubbing, until the lotion dries. you may wash your hair as usual but not right after applying the medicine
3. To apply aerosols, shake well and spray on the affected area holding the container about 3 to 6 inchs away. Sprauy about 2 seconds to cover the area the size of your hand Take care not to inhale the vapors. If you are spraying your or near your face, cover your eyes.
4. Use only as directed. Do not put bandages, dressings, cosmetics or other skin prepn. over the treated areas unless directed by the physician
5. Notify physician, if condition being treated gets worse or if buring , swelling or redness develop.
6. Avoid prolong use around the eyes, in the genital and rectal areas, on the face, armpits, and in skin creases unless directed by your physician. Avoid contact with your eyes.
7. If you forget a dose, apply as as you remember and continue on your regular schedule. If it is time for for the next application, wait and then continue your regular schedule. Do not double doses.
8. For parents and pediatric patients- do not use tight fitting diapers or plastic pants on a child treated in the diaper area, these garments work like occlusive dressings and cause moe of the drug to be absorbed nto your childs body
Interaction with Food:
Take with food
Pregnancy and lactation:
Pregnancy -
Corticosteroids are teratogenic in animlas when administered systemically at relatively doses. Therefore use during pregnancy only if potential benefits outweigh thepotential hazards to the fetus. In pregnant women do not use extensively, do not use in large amounts or for prolonged periods of time.
Lactation-
Excercise caution when administering topical corticosteroids to a nursing mother
Children-
Children may be more susceptible to topical corticosteroid induced hypothalamic -pituitary-adrenal (HPA ) axis suppression and Cushings syndrome than adults because of a larger skin surface area to body ratio